National and Kapodistrian University of Athens
Μελέτη κόστους - χρησιμότητας της θεραπευτικής αντιμετώπισης των ασθενών με υπέρταση στην Ελλάδα
Abstract
dc:descriptionResource allocation decisions between competing alternatives within an organized health system constitute a constant and necessary process, especially within the context of the current economic status quo. Hypertension, one of the major public health issues and, also, one of the major contributors to health care expenditure, could not be an exception. In light of the above, the aim of the present dissertation was to perform an economic evaluation of one of the principal interventions to reduce the disease burden of hypertension, i.e. the pharmacological treatment. For that purpose, a cost – utility analysis of hypertension treatment versus a hypothetical no-treatment strategy, taking into account a long-term timeframe with the development of a Markov model, was used as the primary approach. Secondarily, a short term cost – effectiveness analysis that focused on clinical endpoints, as well as a cost – of – illness analysis of hypertension, were performed. The data for the analyses were derived from a prospective observational study of the management of hypertension in Greece. The results indicated that hypertension treatment represents an intervention accompanied by highly favorable incremental cost – utility ratios (3,539 – 5,485€ per QALY gained), especially for certain patient subgroups, such as men smokers. The short term cost – effectiveness analysis confirmed the clinico-economic value of treatment, specifically focusing on the impact of disease severity, on outcomes. Finally, the cost-of-illness analysis, apart from calculating the average total annual cost per patient with hypertension according to disease severity, also highlited the total economic burden, attributed to the disease. The latter is estimated at 3.6 billion Euros, annually, or 1.6% of the country’s Gross Domestic Product. The outcomes of the present study highlight the significance of hypertension as a health priority, as well as the value of treatment, as a health policy intervention. The data presented here, accompanied with similar data for the major diseases/public health problems can constitute important inputs in the decision making process for the improvement of the allocative efficiency of the system and, consequently, the improvement of the efficiency of health services in terms of health status of the population and, finally, the societal welfare.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Athanasakis, Konstantinos
- Αθανασάκης, Κωνσταντίνος
Subjects
dc:subject × 24- Ανάλυση κόστους-χρησιμότητας
- Ανάλυση κόστους-αποτελεσματικότητας
- Οικονομική αξιολόγηση
- Οικονομικά υγείας
- Υπέρταση
- Ποιοτικώς προσαρμοσμένα έτη ζωής
- Ανάλυση κόστους νόσου
- Μοντέλο Markov
- Cost-utility analysis
- Cost-effectiveness analysis
- Economic evaluation
- Health economics
- Hypertension
- Quality adjusted life years (QALY)
- Cost-of-illness analysis
- Markov model
- Ιατρική και Επιστήμες Υγείας
- Άλλες Ιατρικές Επιστήμες
- Κοινωνικές Επιστήμες
- Οικονομικά και Επιχειρήσεις
- Medical and Health Sciences
- Other Medical Sciences
- Social Sciences
- Economics and Business
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/31760